Enrollment finished ahead of schedule in a Phase 2 trial testing Calluna Pharma’s experimental CAL101 therapy in adults with ...

Fast shallow breathing (tachypnea) is one of several breathing difficulties experienced by pulmonary fibrosis (PF) patients. Breathing problems are common in PF because the disease causes progressive ...

Abnormalities in DNA methylation, a genetic modification, may affect disease risk in idiopathic pulmonary fibrosis, according ...

Since leaving the workforce due to IPF, columnist Sam Kirton has been volunteering to be of service to his PF and local communities.

Columnist Kylene Henderson's husband, Donnie, had to pivot in many aspects of life due to PF, including changing his career.

Pulmonary fibrosis (PF) is characterized by the formation of scar tissue in the lungs, which impairs their normal function and makes it harder for oxygen to reach the bloodstream. Despite varying from ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data ...

Enrollment has been completed for a Phase 2b trial that’s testing LYT-100 (deupirfenidone), PureTech Health’s experimental therapy for idiopathic pulmonary fibrosis (IPF). The trial, called ELEVATE ...

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...